GCGregory C. Connolly

Gregory C. Connolly

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gregory C. Connolly has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Platelets and Cancer-Associated Thrombosis

    by Gregory C. Connolly, Richard P. Phipps, Charles W. Francis


  • Prevalence and Clinical Significance of Incidental and Clinically Suspected Venous Thromboembolism in Lung Cancer Patients

    by Gregory C. Connolly, Laurel Menapace, Saman Safadjou, Charles W. Francis, Alok A. Khorana


  • Open Access

    Diabetes mellitus impacts risk of macrovascular invasion in patients undergoing transplantation for hepatocellular carcinoma

    by Gregory C Connolly, Saman Safadjou, Randeep Kashyap, Rui Chen, Mark S Orloff, Aram F Hezel

    Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC), though the basis for this is unknown.


  • Diabetes Mellitus Is Associated With the Presence of Metastatic Spread at Disease Presentation in Hepatocellular Carcinoma

    by Gregory C. Connolly, Saman Safadjou, Rui Chen, Afamefuna Nduaguba, Richard Dunne, Alok A. Khorana, Aram F. Hezel

    Purpose: Diabetes mellitus (DM) is identified as a negative prognostic indicator in hepatocellular carcinoma (HCC). Methods: A retrospective review of HCC patients was conducted to assess the effect of DM on clinical variables. Results: Ninety-seven of 265 (34%) patients had DM at the time of diagnosis. Distant metastasis was found in 33% (30/91) of patients with DM compared with only 9.7% (17/174) of those without DM (OR: 4.5, 95% CI: 2.3–8.8, p < .0001). This difference remained significant when adjusting for other clinical variables (OR: 10.0, 95% CI: 3.9–25.7, p < .0001). Conclusions: DM is associated with the presence of metastatic disease among a single institution cohort of HCC patients.


  • Does bevacizumab increase the risk of venous thromboembolism? A cohort study.

    by A. A. Khorana, G. C. Connolly, M. R. Dalal, J. Lin

    E19543 Background: Bevacizumab has been associated with thrombotic events in cancer patients, but results from recent pooled analyses of clinical trials have produced conflicting data. Methods: Data were extracted from the IMS Patient-Centric Database of commercially insured patients in the United States. Demographics/clinical characteristics of ambulatory adult patients with cancer who were initiating chemotherapy (n=17,284) and a matched control cohort without cancer (n=17,284) were evaluated. Incidence of venous thromboembolism (VTE), bleeding, resource utilization, and cost were recorded during a follow-up period of 3-12 months after initiation of chemotherapy in the cancer cohort. Data from the entire cancer cohort and sub-cohort with colorectal cancer only were analyzed. Results: Overall, 2,170 (12.6%) patients experienced VTE in the cancer cohort compared with 237 (1.4%) in the control cohort (P<0.0001). The incidence of VTE events among cancer patients included 7.7% (n=1,336) deep vein thrombosis, 2.4% (n=406) pulmonary embolism, and 2.5% (n=428) both. The respective bleeding rates were 22.4% (n=3,873) and 7.0% (n=1,211; P<0.0001). Among patients with cancer, 11.8% (n=2,035) received bevacizumab. Patients treated with bevacizumab had a significantly increased risk of any VTE event (odds ratio [OR], 1.43; 95% confidence interval [CI], 1.24, 1.65; P<0.0001) and bleeding (OR, 1.39; 95% CI, 1.23, 1.57; P<0.0001) compared with patients not treated with bevacizumab. Of 4,548 patients with colorectal cancer, 480 (10.6%) experienced VTE; 1,135 (25.0%) received bevacizumab. Colorectal cancer patients treated with bevacizumab had a significantly increased risk of VTE (OR, 1.66; 95% CI, 1.32, 2.10; P<0.0001) and bleeding (OR, 1.51; 95% CI, 1.24, 1.83; P<0.0001) compared with those not treated with bevacizumab. Conclusions: The risk of VTE was high among this cohort of ambulatory patients with cancer and sub-cohort of patients with colorectal cancer. The incidence of VTE and bleeding was increased further in those who were treated with bevacizumab. Study funding and editorial support provided by sanofi-aventis U.S.


  • Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer.

    by G. C. Connolly, M. R. Dalal, J. Lin, A. A. Khorana

    7066 Background: The incidence of VTE among lung cancer patients reported in hospital-discharge database studies and single-institution studies is 2%-13%. The incidence and economic impact of lung cancer–associated VTE is unknown in the ambulatory setting, where most cancer care occurs. This retrospective cohort analysis examined incidence and risk factors for VTE in ambulatory patients with primary lung tumors who were starting chemotherapy. Methods: Data were extracted from the IMS Patient-Centric database, a large administrative database of US healthcare claims. Demographics/clinical characteristics and healthcare resource utilization of patients with solid tumors, including lung, and patients in a matched control cohort without cancer were evaluated. The incidence of deep vein thrombosis (DVT), pulmonary embolism (PE), and DVT+PE was recorded during 3- to 12-month follow-up after chemotherapy initiation in the lung cancer cohort. Results: Lung cancer (n=6,732) and control (n=17,284) cohorts had 51% women, with a mean age of 64 years. Respective mean Charlson Comorbidity Index (CCI) scores were 6.7 and 0.6. VTE occurred in 13.9% of the lung cancer cohort (odds ratio [OR], 3.15; 95% confidence interval [CI], 2.55, 3.89) and 1.4% of the control cohort (P<0.0001). The incidence of DVT, PE, and DVT+PE was 7.4%, 3.6%, and 2.9%, respectively, in the lung cancer cohort vs 1.0%, 0.2%, and 0.2% in the control cohort (P<0.0001 for all comparisons). The use of erythropoiesis-stimulating agents (ESAs; OR, 1.63; 95% CI, 1.40, 1.89; P<0.0001 vs no ESA), CCI ≥5 (OR, 2.56; 95% CI, 1.02, 6.39; P=0.045 vs CCI <5), and congestive heart failure (CHF; OR, 1.29; 95% CI, 1.01, 1.66; P=0.045 vs no CHF) were associated with VTE. Bleeding occurred in 22.1% of the lung cancer cohort and 7.0% of the control cohort (P<0.0001). Among lung cancer patients, VTE was associated with a 39.5% higher total medical cost than non-VTE (P<0.0001). Conclusions: VTE is highly prevalent among patients with lung cancer receiving chemotherapy and is associated with a significant increase in healthcare resource utilization. Disclosure: Study funding and editorial support provided by sanofi-aventis U.S.